Skip to main content

Table 3 Adverse effects.

From: Chlorpromazine for schizophrenia: a Cochrane systematic review of 50 years of randomised controlled trials

  No. of trials Chlorpromazine Placebo RR (95% CI) Random
   events/total participants  
General symptoms
Sedation 18 224/725 68/517 2.30 (1.7–3.1)
Weight gain > 10 lb; 4.5 Kg 5 31/75 7/90 4.44 (2.1–9.3)
Extrapyramidal symptoms
Acute dystonia 4 28/472 5/306 3.10 (1.3–7.7)
Parkinsonism 12 123/723 40/542 2.60 (1.2–5.4)
Fits 3 19/450 4/245 2.41 (0.4–16.4)
Akathisia 8 53/602 40/400 0.95 (0.5–1.9)
Allergic-type symptoms
Agranulocytosis/leucopenia 7 10/207 2/187 2.02 (0.7–5.6)
Rashes/itching 11 42/658 21/475 1.43 (0.9–2.4)
Jaundice 3 8/116 1/115 4.04 (0.9–17.9)
Photosensitivity 6 81/496 9/303 5.19 (2.7–9.8)
Eye opacity 2 97/431 16/226 3.09 (1.9–5.1)
Anti-cholinergic/nor-adrenergic symptoms
Hypotension + dizziness 15 113/708 38/524 1.90 (1.4–2.7)
Constipation 9 40/590 16/365 1.68 (0.9–2.9)
Urinary retention 3 11/459 5/253 1.49 (0.5–4.3)
Dry mouth 5 32/473 4/283 4.00 (1.6–9.8)
Blurred vision 6 10/529 9/381 1.10 (0.5–2.9)